Live Breaking News & Updates on Presentation Title

Stay updated with breaking news from Presentation title. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , San-francisco , California , United-kingdom , Stanford-university , Tennessee , Riley-bove , Lawrence-steinman , Sclerosis-international-federation , Pediatrics-at-stanford-university , Linkedin , Exchange-commission

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy. ....

Chicago , Illinois , United-states , Mccormick-place , American , Theodore-jenkins , Leslyem-heisler , Kyle-evans , Charu-aggarwal , Company-nasdaq , Business-development , Exchange-commission

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 RE

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio. ....

Ann-arbor , Michigan , United-states , Spain , Madrid , Hall-goya , Kristenm-pettit , Corey-davis , Division-of-hematology-oncology , Department-of-internal-medicine , Network-of-companies , University-of-michigan

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up ...

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up ...
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

Spain , Michigan , United-states , Ann-arbor , Madrid , Hall-goya , Kristenm-pettit , Corey-davis , Nasdaq , University-of-michigan , Virginia-amannentente-network-of-companies , Department-of-internal-medicine

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Madrid , Spain , United-states , Michigan , Ann-arbor , Hall-goya , Kristenm-pettit , Corey-davis , Department-of-internal-medicine , Division-of-hematology-oncology , Nasdaq , Protagonist-therapeutics-inc